Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 12:40 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 101 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Lansoprazole Clear all
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Bioequivalence Study of Dexlansoprazole Capsules From Two Manufacturing Plants

NCT03131895
View directory record Official record
Conditions
Healthy Volunteers
Interventions
30 mg dexlansoprazole capsules manufactured at TOB, 30 mg dexlansoprazole capsules manufactured at TPC, 60 mg dexlansoprazole capsules manufactured at TOB, 60 mg dexlansoprazole capsules manufactured at TPC
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 55 Years
Enrollment
116 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jun 14, 2019 · Synced Oct 17, 2026, 12:40 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Open-label PK Study to Evaluate Lansoprazole and Neratinib in Healthy Subjects

NCT02334501
View directory record Official record
Conditions
Healthy
Interventions
Lansoprazole, Neratinib
Drug
Lead sponsor
Puma Biotechnology, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated May 11, 2016 · Synced Oct 17, 2026, 12:40 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Lansoprazole 30 mg DR Capsule Replicate Food Study

NCT01046084
View directory record Official record
Conditions
Healthy
Interventions
Lansoprazole, Prevacid®
Drug
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003
U.S. locations
1
States / cities
Saint Charles, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 8, 2010 · Synced Oct 17, 2026, 12:40 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of the Effects of Multiple Doses of Dexlansoprazole, Lansoprazole, Omeprazole or Esomeprazole on the Pharmacokinetics and Pharmacodynamics of Clopidogrel in Healthy Participants.

NCT00942175
View directory record Official record
Conditions
Healthy
Interventions
Clopidogrel, Clopidogrel and Lansoprazole, Clopidogrel and Dexlansoprazole, Clopidogrel and Omeprazole, Clopidogrel and Esomeprazole
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 55 Years
Enrollment
160 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Feb 3, 2012 · Synced Oct 17, 2026, 12:40 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Dexlansoprazole Delayed-Release Capsules in Treating Symptomatic Non-Erosive Gastroesophageal Reflux Disease in Adolescents

NCT01642602
View directory record Official record
Conditions
Gastroesophageal Reflux Disease
Interventions
Dexlansoprazole
Drug
Lead sponsor
Takeda
Industry
Eligibility
12 Years to 17 Years
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
35
States / cities
Huntsville, Alabama • Mobile, Alabama • Phoenix, Arizona + 32 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2014 · Synced Oct 17, 2026, 12:40 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Dexlansoprazole Modified Release Formulation to Treat Heartburn

NCT00251745
View directory record Official record
Conditions
Gastroesophageal Reflux Disease
Interventions
Dexlansoprazole MR, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
908 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
95
States / cities
Alabaster, Alabama • Birmingham, Alabama • Huntsville, Alabama + 92 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2011 · Synced Oct 17, 2026, 12:40 PM EDT
Completed Phase 2 Interventional Results available

A Trial of IW-3718 for 8 Weeks in Patients With Symptomatic Gastroesophageal Reflux Disease (GERD)

NCT02637557
View directory record Official record
Conditions
Gastroesophageal Reflux Disease
Interventions
IW-3718, Matching Placebo, PPI
Drug
Lead sponsor
Ironwood Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
282 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
62
States / cities
Dothan, Alabama • Phoenix, Arizona • Tucson, Arizona + 54 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2019 · Synced Oct 17, 2026, 12:40 PM EDT
Completed Phase 4 Interventional

Effect of Prevacid on Prostaglandin Levels in Patient With Stress Ulcer

NCT00239551
View directory record Official record
Conditions
Stomach Ulcer
Interventions
Prevacid
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 31, 2013 · Synced Oct 17, 2026, 12:40 PM EDT
Completed Early Phase 1 Interventional

Effectiveness of Physiologic Testing in PPI Non-Responders

NCT03202537
View directory record Official record
Conditions
Gastro Esophageal Reflux
Interventions
dexlansoprazole
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 80 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 12, 2023 · Synced Oct 17, 2026, 12:40 PM EDT
Completed Phase 1 Interventional Results available

Study to Evaluate the Pharmacokinetics and Safety of Dexlansoprazole in Pediatric Subjects With Symptomatic Gastroesophageal Reflux Disease

NCT01045096
View directory record Official record
Conditions
Gastroesophageal Reflux
Interventions
Dexlansoprazole
Drug
Lead sponsor
Takeda
Industry
Eligibility
1 Year to 11 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
4
States / cities
Anaheim, California • Miami Garden, Florida • Kansas City, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 5, 2012 · Synced Oct 17, 2026, 12:40 PM EDT
Terminated Phase 4 Interventional

Lansoprazole Preventing Gastroduodenal Stress Ulcerations

NCT00220909
View directory record Official record
Conditions
Patients Undergoing Elective Coronary Artery Bypass Graft
Interventions
Lansoprazole
Drug
Lead sponsor
Temple University
Other
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 11, 2008 · Synced Oct 17, 2026, 12:40 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study Evaluating The Potential Effect Of Lansoprazole On The Pharmacokinetics Of Bosutinib In Healthy Subjects

NCT00952913
View directory record Official record
Conditions
Healthy
Interventions
Bosutinib, Lansoprazole
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years to 50 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Apr 19, 2011 · Synced Oct 17, 2026, 12:40 PM EDT
Completed Phase 3 Interventional

Efficacy/Safety of Lansoprazole in Patients With Frequent Heartburn

NCT00390390
View directory record Official record
Conditions
Heartburn
Interventions
Lansoprazole
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
576 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
30
States / cities
Mobile, Alabama • Little Rock, Alaska • Chandler, Arizona + 26 more
Source: ClinicalTrials.gov public record
Updated May 25, 2010 · Synced Oct 17, 2026, 12:40 PM EDT
Completed Phase 3 Interventional

Efficacy/Safety of Lansoprazole in Patients With Frequent Heartburn

NCT00389948
View directory record Official record
Conditions
Heartburn
Interventions
Lanzoprazole
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
576 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
28
States / cities
Hoover, Alabama • Huntsville, Alabama • Sierra Vista, Arizona + 23 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2007 · Synced Oct 17, 2026, 12:40 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

The Effects of Dexlansoprazole for the Treatment of Throat-Related Reflux

NCT01317472
View directory record Official record
Conditions
Laryngopharyngeal Reflux
Interventions
dexlansoprazole, Placebo
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Oct 1, 2019 · Synced Oct 17, 2026, 12:40 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Lansoprazole 30 mg DR Capsule Fasting Study

NCT01045967
View directory record Official record
Conditions
Healthy
Interventions
Lansoprazole, Prevacid®
Drug
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Dec 8, 2010 · Synced Oct 17, 2026, 12:40 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy Study of Fentanyl Buccal Tablet Use in the Emergency Department for Isolated Extremity Injury

NCT01270659
View directory record Official record
Conditions
Pain
Interventions
Fentanyl, oxycodone/acetaminophen
Drug
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years to 60 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Tulsa, Oklahoma
Source: ClinicalTrials.gov public record
Updated Jun 20, 2017 · Synced Oct 17, 2026, 12:40 PM EDT
Completed Phase 1 Interventional

Can E-cadherin Found in Tissue/Blood be Valuable in Identifying & Monitoring Patients With Post-proton Pump Inhibitor (PPI)-Responsive Heartburn

NCT01149395
View directory record Official record
Conditions
Heartburn, Gastroesophageal Reflux Disease
Interventions
Dexlansoprazole
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 75 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 19, 2016 · Synced Oct 17, 2026, 12:40 PM EDT
Completed Phase 1 Interventional Results available

Pharmacokinetic and Safety of Dexlansoprazole in Adolescents With Gastroesophageal Reflux Disease

NCT00847210
View directory record Official record
Conditions
Gastroesophageal Reflux
Interventions
Dexlansoprazole MR
Drug
Lead sponsor
Takeda
Industry
Eligibility
12 Years to 17 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
3
States / cities
Anaheim, California • Cypress, California • Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Feb 2, 2012 · Synced Oct 17, 2026, 12:40 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Dexlansoprazole MR and Lansoprazole on Healing of Erosive Esophagitis

NCT00251719
View directory record Official record
Conditions
Esophagitis, Reflux, Esophagitis, Peptic
Interventions
Dexlansoprazole MR, Lansoprazole
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
2,054 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
100
States / cities
Anniston, Alabama • Hueytown, Alabama • Huntsville, Alabama + 97 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2012 · Synced Oct 17, 2026, 12:40 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Study to Assess the Relative Bioavailability of Fixed-Dose Combination (FDC) Tablet (Simeprevir, Odalasvir and AL-335) Compared With Single Agents Administered Together, and to Assess the Effect of Multiple-Dose Lansoprazole or Omeprazole on Single-Dose Pharmacokinetics of SMV, ODV, and AL-335 (FDC)

NCT03059303
View directory record Official record
Conditions
Healthy
Interventions
Simeprevir 75 mg, Odalasvir 25 mg, Odalasvir 12.5 mg, Odalasvir 75 mg, AL-335 800 mg, Lansoprazole 30 mg, Omeprazole 20 mg
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Dec 22, 2017 · Synced Oct 17, 2026, 12:40 PM EDT
Completed Phase 3 Interventional

The Use of Lansoprazole to Treat Infants With Symptoms of Gastroesophageal Reflux

NCT00324974
View directory record Official record
Conditions
Gastroesophageal Reflux Disease
Interventions
Lansoprazole microgranules suspension, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
1 Month to 11 Months
Enrollment
162 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
9
States / cities
Tampa, Florida • Park Ridge, Illinois • Shreveport, Louisiana + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2010 · Synced Oct 17, 2026, 12:40 PM EDT
Completed No phase listed Observational

Reflux Disease Therapy in the Management of Childhood Asthma-data Entry and Analysis Only

NCT01536457
View directory record Official record
Conditions
Asthma, Gastroesophageal Reflux Disease
Interventions
Not listed
Lead sponsor
Children's Center for Digestive Health Care
Other
Eligibility
4 Years to 11 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Feb 11, 2015 · Synced Oct 17, 2026, 12:40 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetic Study of Lansoprazole in Cystic Fibrosis

NCT00458614
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Lansoprazole
Drug
Lead sponsor
Arkansas Children's Hospital Research Institute
Other
Eligibility
2 Years to 10 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Jan 11, 2011 · Synced Oct 17, 2026, 12:40 PM EDT